Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Hong Kong
Pharma
Generic tariffs, Samsung Bio, HK IPO—Fierce Pharma Asia
President Trump unveiled generic drug tariffs. Samsung Bio will buy PolyPepide for $1.8 billion. A U.S. biotech seeks an IPO first in Hong Kong.
Angus Liu
Jul 24, 2026 9:00am
Novartis-Argo, Eisai, Henlius—Fierce Pharma Asia
Sep 5, 2025 9:00am
Visen Pharmaceuticals files for $86M IPO in Hong Kong
Mar 21, 2025 7:05am
Lilly-Innovent, Novartis, Moderna and more—Fierce Pharma Asia
Feb 18, 2022 9:15am
Moderna, Eli Lilly, AstraZeneca and more—Fierce Pharma Asia
Feb 12, 2021 10:45am
An IPO will make one of the world's richest biopharma families
Jun 13, 2019 11:47am
